skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

12013

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women



Review

(2639) Total Article Views


Authors: Vogel VG

Published Date October 2011 Volume 2011:3 Pages 127 - 137
DOI: http://dx.doi.org/10.2147/BCTT.S11288

Victor G Vogel
Cancer Institute, Geisinger Health System, Danville, PA, USA

Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of breast cancer among first-degree relatives (mother, sisters, daughters) also increases risk. Quantitative measures of risk give accurate predictions of breast cancer incidence for groups of women but not for individual subjects. Multiple published, randomized controlled trials, which employed selective estrogen receptor (ER) modulators (SERMs), have demonstrated consistent reductions of 35% or greater in the risk of ER-positive invasive and noninvasive breast cancer in postmenopausal women. Professional organizations in the US now recommend the use of SERMs to reduce the risk of breast cancer in high-risk, postmenopausal women. Raloxifene and tamoxifen reduce the risk of ER-positive invasive breast cancer with equal efficacy, but raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality. Overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with raloxifene use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxifen use.

Keywords: selective estrogen receptor modulators (SERMs), raloxifene, risk reduction, chemoprevention



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Victor Vogel


Readers of this article also read:
  • ASCO 2013 Meet the Editor

    We invite you to meet Prof Dr Hans-Joachim Schmoll at the Dove Medical Press booth 22102 on June 1st at 11am. Prof Dr Schmoll is the Editor-in-Chief of the journal OncoTargets and Therapy (IF 1.26).